Related Experiment Videos
The management of paroxysmal tachycardias using the Cybertach-60
Insights
The Cybertach-60 pacemaker effectively manages reentrant tachycardias, particularly supraventricular tachycardia, with high long-term survival rates. This device offers a reliable solution for patients requiring arrhythmia management.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Reentrant tachycardias pose significant risks.
- Pacemaker technology has advanced for arrhythmia management.
Purpose of the Study:
- To evaluate the long-term efficacy of the Cybertach-60 pacemaker.
- To assess patient outcomes for supraventricular and ventricular tachycardia.
Main Methods:
- A cohort of 143 patients received the Cybertach-60 pacemaker.
- Patients were treated for supraventricular (91) and ventricular (52) tachycardia.
- Follow-up averaged 1.8 years for SVT and 1.1 years for VT.
Main Results:
- 82% of supraventricular tachycardia patients survived with the pacemaker as primary therapy.
- 58% of ventricular tachycardia patients survived, utilizing the device for termination.
- No documented deaths in the VT group were linked to arrhythmia or pacemaker activity.
Conclusions:
- The Cybertach-60 demonstrates long-term effectiveness in managing reentrant tachycardias.
- It is particularly effective for supraventricular tachycardia management.
- The device offers a viable therapeutic option for patients with recurrent tachyarrhythmias.
Abstract:
The Cybertach-60 is a bipolar multiprogrammable pacemaker designed for the automatic detection and termination of reentrant tachycardias using bursts of rapid pacing. From August 1979 to March 1984 in the U.S.A., 143 patients received the device; 91 for supraventricular and 52 for ventricular tachycardia. After a mean follow-up period of 1.8 years, 82% of patients with supraventricular tachycardia remain alive with the implanted pacemaker providing the principal therapy for the arrhythmia. Of those patients with ventricular tachycardia, 30 (58%) remain alive (mean follow-up 1.1 years) and use the device for tachycardia termination. In this group there were 18 patient deaths: 14 documented and not sudden; 4 sudden and not documented. None of the 14 documented deaths were a result of arrhythmia or pacemaker activity. The Cybertach-60 has proved to be effective in the long-term management of patients with reentrant rhythms, particularly supraventricular tachycardia.